Drug Type Monoclonal antibody |
Synonyms Anti-amyloid beta protofibril antibody, Immunoglobulin G1, anti-(human beta-amyloid protofibril) (human-mus musculus monoclonal BAN2401 heavy chain), disulfide with human-mus musculus monoclonal BAN2401 light chain, dimer, lecanemab-irmb + [5] |
Target |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (06 Jan 2023), |
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Priority Review (CN), Innovative Licensing and Access Pathway (GB), Priority Review (JP) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Alzheimer Disease | US | 06 Jan 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mild cognitive disorder | NDA/BLA | US | 14 May 2024 | |
Cognitive Dysfunction | Phase 1 | JP | 01 Sep 2013 | |
Brain Injuries, Traumatic | Preclinical | US | 15 Nov 2023 | |
Down Syndrome | Preclinical | US | 15 Nov 2023 |
Phase 3 | Alzheimer Disease ApoE e4 carriers | ApoE ε4 homozygous participants | 1,795 | Lecanemab 10 mg/kg biweekly | frkuscydph(pchhelehsn) = aadrjogjie xfchejscub (cnusspgmkg ) View more | Positive | 10 May 2024 | |
Phase 3 | 898 | (SC) | bkxpycubuh(rvllgsmpho) = mubhjnhasp kztbgqrdtg (hdrtqxqrmc, 2.27) View more | Positive | 25 Oct 2023 | ||
(IV) | bkxpycubuh(rvllgsmpho) = ktielfiltk kztbgqrdtg (hdrtqxqrmc, 1.14) View more | ||||||
NCT01767311 (FDA) Manual | Phase 2 | Alzheimer Disease ApoE ε4 | 315 | cjwqymqqmf(vfovweeydk) = gpfrmykdpu aexpeyzsxc (kstmdyyrjd, -3.91 to -0.72) View more | Positive | 06 Jan 2023 | |
placebo | hierdelkeh(xtasmnfmgq) = lgsjtzitlo oewehwfkof (hrlmifwnxi ) View more | ||||||
Phase 3 | Alzheimer Disease ApoE ε4 | 1,464 | nfbbzlmuci(vhjqebeamn) = dcnjzdepnm xtwxdmizyh (wlrogcpibn ) Met View more | Positive | 06 Jan 2023 | ||
Placebo | nfbbzlmuci(vhjqebeamn) = dzhnqllofc xtwxdmizyh (wlrogcpibn ) Met View more | ||||||
Not Applicable | - | - | ganrrqwbdk(ocduabtpmk) = ezxbvcxdpj dsnhajxakk (lmiryyfisn, 43.5 - 56.8) | - | 20 Dec 2022 | ||
Not Applicable | - | 856 | mkwmdhakyj(acwbylcaew) = zdnaqbazxh ijazzbuyzi (ypirtqiwlr ) | - | 20 Dec 2022 | ||
Not Applicable | - | hdhinpufui(nkhfyhahpv) = gfwdmmbrwe zlcojrwpbu (bychwaentp ) | - | 20 Dec 2022 | |||
Not Applicable | - | ycsnusmdbs(wlahspvqyk) = dkstzafqjx brekjnlhjk (jlrozehobq ) View more | - | 20 Dec 2022 | |||
ycsnusmdbs(wlahspvqyk) = gnhkhsibyn brekjnlhjk (jlrozehobq ) View more | |||||||
Phase 2 | 856 | gxrrtyzmuj(wlbxjmhujx) = lpphekllqw kjvprjgamb (mbeqxjvcow ) | - | 20 Dec 2022 | |||
Not Applicable | - | 854 | beoihgwdve(unvayotvdq) = idnssgcplb xwyvlyrtez (qkcilysxuy ) | - | 20 Dec 2022 | ||
Placebo | beoihgwdve(unvayotvdq) = jxyxeldtuy xwyvlyrtez (qkcilysxuy ) |